TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06469060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant anti-PD-1 with DOC chemotherapy
Description: Patients were treated with one cycle of Tislelizumab 200 mg monotherapy on day~1. At 3 weeks and with intervals of 3 weeks between each cycle (weeks 3, 6, 9 and 12), patients received a total of four combination cycles consisting of Tislelizumab 200 mg, docetaxel 50 mg m-2 and oxaliplatin 100 mg m-2 intravenously at the beginning of each cycle, plus oral capecitabine 850 mg m-2 twice daily on days 1-14 of each cycle.
Study: NCT05154695

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: The eligible participants first received LLLT with a 685-nm wavelength and an output of 30 mW at energy densities of 8 J/cm2 at trigger point of upper trapezius muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A.therapeutic ultrasound group
Description: Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A.therapeutic ultrasound group
Description: Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B.prolotherapy group
Description: Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B.prolotherapy group
Description: Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
Study: NCT05623293

Intervention type: DIAGNOSTIC_TEST
Intervention: eye - Optcial coherence tomography
Description: pre and postoperative
Study: NCT06215833

Intervention type: DRUG
Intervention: Propofol
Description: All children will undergo anesthesia via Propofol bolus injection in induction then Propofol infusion in maintenance of anesthesia and will be given after total recovery, Cetal suppositories as postoperative analgesia

Intervention type: DRUG
Intervention: Sevoflurane
Description: All children will undergo anesthesia via Sevoflurane will be given during induction then through maintenance of anesthesia and will be given after total recovery, Cetal suppositories as post operative analgesia
Study: NCT06593600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Subcutaneous (SC) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7544
Description: Subcutaneous (SC) administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC administration
Study: NCT06656078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1. WORKING MEMORY TASK:
Description: Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1. WORKING MEMORY TASK:
Description: Arithmetic task: backward counting with serial 3 subtractions out loud. Group 1 and Group 2 participants will be asked to count backwards with serial 3 subtractions out loud while walking 10 meters. There is considerable disruption of performance because of simultaneous articulatory suppression. However, when errors were observed they were calculated to be numerically close to the correct figure which suggests that performance was not completely disrupted by suppression of articulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2. VISUAL AND VERBAL FLUENCY TASK
Description: Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2. VISUAL AND VERBAL FLUENCY TASK
Description: Modified Stroop test or Stroop colour word test: Participants are asked to name the colour of ink that each word is printed. It is the most frequent test used to show attention bias in anxiety patients. This test will appear on the mobile phone in their hands while they walk to increase the effect of cognitive loading.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3. MOTOR TASK:
Description: Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
Study: NCT05083858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Physiotherapy Program + Cervical Stabilization Exercises
Description: First of all, patients will be taught correct craniocervical flexion movement without activation of superficial muscles in different positions (supine, prone, crawling, sitting, standing). The program will be continued by asking to maintain the cranio-cervical flexion position during all movements. In order to gain dynamic stabilization, unilateral, bilateral, contralateral, ipsilateral and reciprocal extremity movements will be added to the program together with craniocervical flexion movement. Resistance will be added to the exercises as control of the movement is achieved. The exercises will progress from static to dynamic, from stationary floors to moving floors, from simple movements to complex movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Physiotherapy Program + Oculomotor Exercises
Description: Oculomotor Exercises is a program consisting of exercises that support proprioception in the cervical region. It consists of 4 main contents; Sacadic Eye movements, Gaze stability, Head/eye coordination, Head repositioning exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical Physiotherapy Program
Description: Conventional TENS will be applied to apply analgesic current. TENS application will be made to the cervical paravertebral region, using four 5 x 5 cm adhesive surface electrodes, at 80 Hz frequency for 20 minutes, 100 msec.~All participants will be asked to lie in a prone position. The neck will be in a neutral position. The hot pack will be applied to the cervical region for 20 minutes.~Classical massage will be applied for 20 minutes using the Swedish technique. The technique will be performed on the upper and neck region of the back with 3 strokes, 3 kneading and 3 strokes. The patient will be massaged while lying in the prone position.~Stretching/Posture Exercises Exercises will be applied as a 5-10 minute warm-up-cool-down program at the beginning and end of the study. Cervical flexor, lateral flexor, rotator muscles, pectorals, inferior shoulder joint capsule will be stretched. In addition to this, posture exercises will also be done.
Study: NCT06656078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3. MOTOR TASK:
Description: Carrying a tray with four glasses filled with water. Participants will be asked to hold a tray of glasses filled with water and walk 10 meters to calculate the effect of cognitive loading on gait.
Study: NCT06660654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raludotatug deruxtecan
Description: IV administration Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raludotatug deruxtecan
Description: IV administration Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raludotatug deruxtecan
Description: IV administration Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raludotatug deruxtecan
Description: IV administration Q3W
Study: NCT05844215

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP-9 and TIMP-1
Description: Examine level of serum MMP-9 and TIMP-1

Intervention type: DIAGNOSTIC_TEST
Intervention: MMP-9 and TIMP-1
Description: Examine level of serum MMP-9 and TIMP-1
Study: NCT06660654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raludotatug deruxtecan
Description: IV administration Q3W
Study: NCT06662890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supersaturated oxygen
Description: Supersaturated O2 (SSO2) therapy immediately following primary percutaneous coronary intervention (PCI) using radial artery access in the cardiac catheter laboratory.~https://www.zoll.com/products/supersaturated-oxygen-therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: Control (sham) procedure involving wrist manipulation in addition to standard care.
Study: NCT06599502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0022
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.
Study: NCT06438081

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cook double-balloon catheter
Description: To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Cook double-balloon catheter
Description: To compare whether Cook double-balloon catheter or Propess able to achieve vaginal delivery with a shorter priming to delivery interval
Study: NCT04880187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXA1125
Description: AXA1125 administered BID with or without food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXA1125
Description: AXA1125 administered BID with or without food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo administered BID with or without food
Study: NCT05490797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: app based training with conventional therapy
Description: The experimental group will receive an additional mobile application therapy including , dexterity fine motor skills, bowling game, scribble game and peglight game in addition to the conventional therapy for hand function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional hand function rehabilitation therapy including, strengthening exercises which consist of palm down wrist flexion exercise, dexterity( shifting exercise) and fine motor skills(nine peg hole exercise)
Study: NCT06599502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0022
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0022
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0022
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0022
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0022
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0022
Description: AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab (Erbitux®) is a recombinant chimeric human/mouse Immunoglobulin G monoclonal antibody which binds to EGFR and competitively inhibits the binding of EGFR and other ligands
Study: NCT06596616

Intervention type: OTHER
Intervention: Radiology
Description: Radiology - MRI Scans

Intervention type: OTHER
Intervention: Gadopiclenol
Description: Gadopiclenol is a new macrocyclic gadolinium-based contrast agent (GBCA)
Study: NCT06661395

Intervention type: DEVICE
Group type: OTHER
Intervention: Wingate Anaerobic Test with Virtual Reality
Description: Wingate Anaerobic Power Test Protocol, commonly used for assessing anaerobic capacity, involves a warm-up followed by testing. The warm-up includes 5 minutes of dynamic cycling, incorporating sprints. During the test, the athlete pedals at maximum effort for 30 seconds with added weight. Heart rate is monitored, and power output is measured every 5 seconds. Peak and average power values are calculated.~This protocol will be gamified for VR goggles. The warm-up simulates cycling in a forest. Athletes sprint for 5 seconds every minute to escape a train, with prompts on the screen. The testing phase includes a simulated race, with athletes pedaling at maximum effort for 30 seconds to compete against rivals, signaled by flares and a countdown.
Study: NCT06598800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: BG-T187
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: BG-T187
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: BG-T187
Description: Intravenous administration
Study: NCT06675955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab will be administered according to the regimen in the parent study.
Study: NCT04645589

Intervention type: DRUG
Intervention: Myfortic
Description: There is no treatment allocation. Patients administered Myfortic by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05081258

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: passive Alveolar Molding
Description: A passive palate plate (passive Alveolar Molding) will be inserted within the first week after birth. The pAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and the treatment with the pAM appliance will continue until palate closure (10-12 months of life).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasoalveolar Molding
Description: A passive palate plate will be inserted within the first week after birth. A nasal stent will be added to the palate plate after one week (NAM appliance). The NAM appliance will be modified on regular appointments and remain until surgical lip closure (6-7 months of life). After surgical lip closure, infants will receive a nostril retainer and will be treated with a passive palate plate without nasal stent until palate closure (10-12 months of life).
Study: NCT06484647

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention is a procedure that require coronary stenosis dilatation with dilatation catheter balloon and generally stent implantation.~The study involve coronary stenosis at bifurcation level that require complex coronary techniques such as External Minicrush or TAP technique.

Intervention type: PROCEDURE
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention is a procedure that require coronary stenosis dilatation with dilatation catheter balloon and generally stent implantation.~The study involve coronary stenosis at bifurcation level that require complex coronary techniques such as External Minicrush or TAP technique.
Study: NCT04999709

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.
Study: NCT05287438

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next-Generation DNA Sequencing
Description: NGS is a technique of microbiological sequencing, using 16s ribosomal RNA molecular identification has been implemented to detect bacteria and fungi present in the sample

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Culture
Description: Standard of care culture and sensitivity
Study: NCT04753437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: Bismuth potassium citrate tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: Bismuth potassium citrate tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan tablets.
Study: NCT05127746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 5mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aricept 10mg Tablet
Description: 1 tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 A
Description: 1 patch once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 A
Description: 1 patch once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 B
Description: 1 patch once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5207 B
Description: 1 patch once weekly
Study: NCT06246006

Intervention type: OTHER
Intervention: Gene sequencing
Description: Next generation sequencing of candidate genes (JAK2, cMPL, CALR, ASXL1 and NF-E2)
Study: NCT05339867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent Maternal Mortality using Mobile technology (PM3)
Description: PM3: The app will include:~1. integrated self-management and tailored health messaging feature~2. support center based on social support gaps which will also provide a centralized place for identifying healthcare providers and facilities~3. multimedia resource kit comprised of videos, current events, news feeds, podcasts, and support groups related to women's postpartum health and community resources~4. a feature that will update women on maternal and reproductive health policies that impact women.
Study: NCT05827471

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of colon cancer
Description: Clinical diagnosis results

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of colon cancer
Description: Clinical diagnosis results